Form 4: Lipocine Inc. Officer Acquires Restricted Stock Units
SEC Form 4 Filing
Krista Fogarty, Principal Accounting Officer of Lipocine Inc., reports the acquisition of restricted stock units.
Summary
- On March 8, 2024, Krista Fogarty, Principal Accounting Officer of Lipocine Inc., acquired 991 shares of Common Stock.
- These shares were acquired as restricted stock units.
- Following the transaction, Fogarty directly owns 1,727 shares of Lipocine Inc.
- The restricted stock units vest over three years, with one-third vesting on March 8, 2025, and the remaining two-thirds vesting semi-annually over the following two years.
Sentiment
Score: 5
Explanation: This is a neutral informational document regarding stock ownership. It doesn't inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor management's alignment with shareholder interests.
Stakeholder Impact
- The acquisition of restricted stock units aligns the officer's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/08/2024 | Date of transaction: Krista Fogarty acquired 991 restricted stock units. |
| 03/08/2025 | One-third of the restricted stock units will vest. |
| 03/12/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.